The tweet was deleted by the author.
But we saved everything 🙂.
NeoGenomics has introduced TSO500 as a comprehensive tool delivering molecular clarity across various stages of therapeutic development.
From biomarker discovery to resistance detection, as well as trial enrollment, longitudinal monitoring, and patient stratification, TSO500 is designed to support biopharma teams in making informed decisions. This tool aims to enhance the precision and efficiency of drug development processes, highlighting NeoGenomics' commitment to innovation in the biotech industry.